Naomune Yamamoto

Naomune Yamamoto

Auto-generated profile, based on publicly available information

Naomune Yamamoto

Department of Internal Medicine Aino Hospital Osaka Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2009 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
NYNaomune Yamamoto
Naomune Yamamoto
NHNorihiro Hotta
Norihiro Hotta
ETEmiko Takasugi
Emiko Takasugi
MIMotonao Ishikawa
Motonao Ishikawa
SMShougo Murakami
Shougo Murakami
KOKuniaki Otsuka
Kuniaki Otsuka

21 September 2018 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
PDF file
NYNaomune Yamamoto
Naomune Yamamoto
EOEriko Oh
Eriko Oh
AYAyaka Yoshikawa
Ayaka Yoshikawa
MTMasaaki Takai
Masaaki Takai
MYMami Yoshida
Mami Yoshida
MSMasakazu Sugino
Masakazu Sugino

1 June 2021 in Diabetes
Verified
Journal Article
Closed access
MYMami Yoshida
Mami Yoshida
AYAi Yoshida
Ai Yoshida
EOEriko Oh
Eriko Oh
NYNaomune Yamamoto
Naomune Yamamoto
ESEun Sasaki
Eun Sasaki
IKIkuo Koyama
Ikuo Koyama
Purpose: The purpose of this study is to assess the usefulness of liraglutide in elderly patients with type 2 diabetes to prevent progression of dementia. Methods: We retrospectively reviewed 31 outpatients with 65 years of age or older, who have been treated with liraglutide for 6 years (Group G; 12 males/19 females, 73.1 ± 8.6 years-old, HbA1c 7.5 ± 0.4%, 9 patients with cerebrovascular diseases, 8 patients with cardiovascular diseases, 16 patients with insulin therapy). Daily dose of liraglutide was 0.9 mg except 2 patients (0.6 mg). We examined Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on MRI, max-IMT measured by carotid artery ultrasonography, visceral fat area, concentrations of HbA1c and FPG, serum levels of CRP, HDL/LDL cholesterol, and TG, both before and after the treatment. Age, HbA1c, and VSRAD values-matched 16 patients who were treated with linagliptin were analyzed as a control (Group D). Results: After 6 years, VSRAD was significantly deteriorated in Group D (1.06±0.98→1.39±1.05 (p<0.01)) but not in Group G (1.28±0.80→1.39±1.1 (NS)). Max IMT and visceral fat are was significantly improved in Group G (2.41±1.50→2.09±0.84 (p<0.05), 141.1±57.2→127.2±52.9 (p<0.01)), but not in group D (2.04±1.01→1.99±0.68 (NS), 102.4±66.5→106.6±62.7cm2 (NS)). CRP was decreased in Group G (0.12±0.11→0.09±0.12mg/dl (p<0.01)). HbA1c (7.5±0.4 → 7.0±0.5 vs. 7.3±0.3 → 6.8±0.4%), FPG (137±19 → 121±11 vs. 129±12→110±15mg/dl), were significantly improved in both groups (p<0.01). No hypoglycemia requiring medical intervention was observed. Only TG in Group G (167±53→147±34mg/dl (p <0.01)) was improved in lipid parameters. During the 6 years, antidementia drugs were prescribed for 2 patients in both groups. A stroke event was found in a patient of Group D. Conclusion: Liraglutide possibly prevent progression of dementia. The reduction of visceral obesity may contribute to this beneficial effect through anti-arteriosclerosis. Disclosure M. Yoshida: None. A. Yoshida: None. E. Oh: None. N. Yamamoto: None. E. Sasaki: None. S. Yoshida: None. N. Ohsawa: None. M. Sugino: None. I. Koyama: None.

29 March 2023 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
MTMai Tatsuno
Mai Tatsuno
TWTaizo Wada
Taizo Wada
EKEmiko Kato
Emiko Kato
KHKiichi Hirayama
Kiichi Hirayama
MFMichiko Fujisawa
Michiko Fujisawa
RSRyota Sakamoto
Ryota Sakamoto